Luqi Biopharma Secures Nearly RMB 300 Million in Series B+ Financing to Advance Inhaled and Oral Nanobody Therapeutics

PharmaCircleMonitoring shows:RecentlyShanghai Novamab Biopharmaceuticals Co., Ltd. ("Novamab" or "the Company"), based in Zhangjiang, has completed its B+ round of financing, raising nearly 300 million RMB.

This round of financing was led by existing shareholder Qiming, with participation from existing shareholders Jiuyu Investment and Fuhui Venture Capital, as well as new shareholders Nanwan Biofund, Jinhe Capital, Zhaode Investment, Shangli Investment, and Zhongshan Yaoke.

The funds raised in this round will be mainly used for three major directions: first, to advance the companyThe Phase IIb clinical study of the core VHH inhaled nanobody pipeline LQ036 is currently proceeding smoothly with patient enrollment; the second focus is to advance the development and implementation of the oral nanobody platform and related pipelines, further refining the technological platform layout.Third, strengthen team building, supplement core R&D and operation talents, and provide support for the company's sustainable development.

https://www.novamab.com/product/index.html

Novamab focuses on the field of innovative nanobody drug research and development. After years of development, it has established a complete R&D, CMC, and pilot production system, and built a mature nanobody innovation technology platform. It is one of the companies in China with the full-process development capability for inhalable nanobody drugs. The company is deeply engaged in the nanobody sector, focusing on unmet clinical needs, and develops biologic innovative drugs with independent intellectual property rights based on its own technical platform.

In terms of pipeline layout, the company has formed a dual-driven development model of inhaled and oral nanobodies. Among them, the inhaled nanobody pipeline LQ036 focuses on the treatment of respiratory diseases and is currently in the enrollment phase of clinical IIb research. Previous clinical studies have shown good safety and efficacy; the oral nanobody platform breaks through the limitation that traditional antibodies are difficult to administer orally, achieving localized high efficiency, low systemic side effects, and high patient compliance. Currently, relevant pipelines are being developed in an orderly manner.

References:

PharmaCircle Data;

Moxie Pharma pharma.bcpmdata.com (formerly known as Pharma Data Cloud);

http://www.marketscreener.com；

https://www.businesswire.com；

www1.hkexnews.hk/；

https://www.biotechtv.com/post；

https://www.prnewswire.com;

; etc.